D-HOMO-(16-EN)-11BETA-ARYL-4-OESTRENES AS WELL AS METHODS FOR PRODUCING AND APPLYING THEM AS MEDICAMENT

摘要

PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as their pharmaceutically compatible addition salts with acids are described in which X stands for an oxygen atom, the hydroxyimino grouping >N DIFFERENCE OH or two hydrogen atoms, R1 stands for a hydrogen atom or a methyl group, R2 stands for an hydroxy group, a C1-C10 alkoxy or C1-C10 acyloxy group, R11 stands for a fluorine, chlorine or bromine atom, and then R12 and R13 together mean an additional bond or R11 stands for a straight-chain or branched-chain C1-C4-alkyl radical or a hydrogen atom, and then R12 and R13 each mean a hydrogen atom or together mean an additional bond, and R3 and R4 have the usual meanings indicated in the description for competitive progesterone antagonists. The invention further relates to a process for the production of new compounds, pharmaceutical preparations containing these compounds, their use for the production of pharmaceutical agents as well as the new intermediate products necessary for the process. The new compounds have a strong affinity to the gestagen receptor and show strong antigestagen as well as antiglucocorticoid, antimineral corticoid and antiandrogenic properties.